Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

December 31, Top 20 Shareholders

201231_Top_Holders_Report (91)

Categories: News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard January 4, 2021

Related posts

December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials
December 23, 2020

December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial
December 22, 2020

December 21, Epichem Awarded DNDi Extension
December 21, 2020

December 4, Issued Capital
December 4, 2020

November 30, Top 20 Shareholders
December 1, 2020

November 5, AGM Results
November 5, 2020

Recent Articles

January 9, PAA LUMC COVID-19 Research Update
January 8, 2021
December 31, Top 20 Shareholders
January 4, 2021
December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials
December 23, 2020
December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial
December 22, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

PharmAust @PharmAust·

DOGS WITH CANCER NEEDED FOR FREE CLINICAL TRIAL

PharmAust is currently recruiting dogs with B cell lymphoma for a Phase IIb clinical trial with a non-toxic anti cancer drug

Pet owners interested in enrolling their dog need a referral from their vet to their nearest trial centre

Reply on Twitter 1349323220608978947 Retweet on Twitter 134932322060897894712 Like on Twitter 134932322060897894725 Twitter 1349323220608978947

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions